Currently, several EGFR inhibitors have been used in the treatment of cancers, such as tyrosine kinase inhibitors (TKI) (eg erlotinib and gefitinib) and monoclonal antibodies (eg cetuximab and necitumumab).47, 48. Here, EGFR is linked to cancer.